X4 Pharma reports FY2023 net loss $101.2M; cash $115.2M; PDUFA for WHIM syndrome April 30

X4 Pharmaceuticals, Inc

Net loss $19.1M Q4 and $101.2M FY2023; R&D $15.3M Q4 and $72.0M FY2023; SG&A $9.9M Q4 and $35.5M FY2023.
Cash, equivalents, restricted cash and marketable securities of $115.2M at Dec 31, 2023; runway into 2025.
FDA PDUFA target action date April 30, 2024 for mavorixafor in WHIM syndrome; launch preparations underway.
Additional Phase 2 results and global Phase 3 trial initiation for chronic neutropenia expected in 1H24.
No guidance change; projected runway excludes debt drawdowns or potential Priority Review Voucher monetization.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

X4 Pharmaceuticals, Inc reported the full year ended December 31, 2023 results: net income net loss of $101.2 million.

Period: the full year ended December 31, 2023
Net income: net loss of $101.2 million
Result: reported results

Exact text from the filing

X4 reported a net loss of $19.1 million and $101.2 million for the fourth quarter and full year ended December 31, 2023, respectively

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

X4 Pharmaceuticals, Inc reported the fourth quarter ended December 31, 2023 results: net income net loss of $19.1 million.

Period: the fourth quarter ended December 31, 2023
Net income: net loss of $19.1 million
Result: reported results

Exact text from the filing

X4 reported a net loss of $19.1 million and $101.2 million for the fourth quarter and full year ended December 31, 2023, respectively

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

X4 Pharmaceuticals, Inc filing history →

Source: SEC EDGAR

accession 0001628280-24-012372

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.